Second Affiliated Hospital of Nanchang University, Nanchang, China.
Second College of Clinical Medicine, Nanchang University, Nanchang, China.
Aging (Albany NY). 2022 Sep 10;14(18):7416-7442. doi: 10.18632/aging.204280.
Kidney renal clear cell carcinoma (KIRC) is a common and invasive subtype of renal tumors, which has poor prognosis and high mortality. MND1 is a meiosis specific protein that participates in the progress of diverse cancers. Nonetheless, its function in KIRC was unclear. Here, TIMER, TCGA, GEO databases and IHC found MND1 expression is upregulated in KIRC, leading to poor overall survival, and MND1 can serve as an independent prognostic factor. Moreover, enrichment analysis revealed the functional relationship between MND1 and cell cycle, immune infiltration. EdU and transwell assays confirmed that MND1 knockdown surely prohibited the proliferation, migration, and invasion of KIRC cells. Additionally, immune analysis showed that MND1 displayed a strong correlation with various immune cells. Interference with MND1 significantly reduces the expression of chemokines. TCGA and GEO databases indicated that MND1 expression is significantly related to two m6A modification related gene (METTL14, IGF2BP3). Finally, the drug sensitivity analysis revealed 7 potentially sensitive drugs for KIRC patients with high MND1 expression. In conclusion, MND1 can be used as a prognostic biomarker for KIRC and provides clues regarding cell cycle, immune infiltrates and m6A. Sensitive drugs may be an effective treatment strategy for KIRC patients with high expression of MND1.
肾透明细胞癌(KIRC)是一种常见且具有侵袭性的肾肿瘤亚型,其预后较差,死亡率较高。MND1 是一种减数分裂特异性蛋白,参与多种癌症的进展。然而,其在 KIRC 中的功能尚不清楚。在这里,TIMER、TCGA、GEO 数据库和 IHC 发现 MND1 在 KIRC 中表达上调,导致总体生存率降低,并且 MND1 可以作为独立的预后因素。此外,富集分析揭示了 MND1 与细胞周期、免疫浸润的功能关系。EdU 和 Transwell 检测证实 MND1 敲低确实能阻止 KIRC 细胞的增殖、迁移和侵袭。此外,免疫分析表明 MND1 与各种免疫细胞呈强相关性。干扰 MND1 会显著降低趋化因子的表达。TCGA 和 GEO 数据库表明,MND1 的表达与两个 m6A 修饰相关基因(METTL14、IGF2BP3)显著相关。最后,药物敏感性分析显示,高表达 MND1 的 KIRC 患者有 7 种潜在敏感药物。总之,MND1 可以作为 KIRC 的预后生物标志物,并为细胞周期、免疫浸润和 m6A 提供线索。敏感药物可能是高表达 MND1 的 KIRC 患者的有效治疗策略。